Find The Best Stocks With Perfect Trade Setups In Minutes A Day

Stop wasting time looking for the right stocks.  Free training on how to find perfect stock trades that can move 300-1,500%.  Learn the # 1 key to successful stock investing and how to find success even If the market is crashing, rebounding… or just going sideways. (ad)

Do Not Delay - Click Here Now


Jeffries Just Named 5 Pot Stocks To Buy Now

The firm initiated coverage of nine pot stocks and said these 5 are Buys.

Five pot stocks just got a thumbs-up from Jefferies this week as the firm initiated coverage of nine Canadian marijuana growers.

Hey, did you know if you really want to retire early, this free training lays it all out for you! Check it out here.

Jefferies analyst Owen Bennett wrote in a note that he sees the legal weed industry growing to  $50 billion in annual sales over the next decade, compared to just $17 billion this year. Bennett said a “realistic” bullish case could also see the industry growing to as much as $130 billion in sales by 2029 due to the industry’s disruptive nature.

“We see a base-case conservative industry size of over $50 billion by 2029 and a realistic upside size of $130 billion on wider industry disruption,” Bennett wrote. “Global winners to be those that lead in both medical and recreational and have a strong U.S. position. Fears on commoditization are overdone. Expect to see further consolidation, more [mainstream consumer-goods companies] taking positions and near-term focus shifting to performance vs. headlines/capacity expectations.”

For the biggest grower on his Buy list, Bennett sees 25% upside ahead for Aurora Cannabis (NYSE: ACB). The other cannabis stocks he rates a Buy are all smaller growers: Green Organic Dutchman (TSX: TGOD.TO, OTC: TGODF) which he says could see 53% upside, CannTrust Holdings (NYSE: CTST, TSX: TRST.TO) which could climb 25%, OrganiGram Holdings (TSXV: OGI.VN, OTC: OGRMF) which could see a gain of 18%, and Flowr (TSXV: FLWR.VN, OTC: FLWPF) which Bennett says could climb 7% in the next twelve months.

CannTrust recently listed on the NYSE, and Chief Executive Peter Aceto told MarketWatch early this week that he hopes the move will “broaden our investor base and give more investors access to the company,” he said.

Aceto also believes that the company is “well positioned” to take advantage of the global opportunity for both medical and recreational cannabis, which he says could be a market worth hundreds of billions of dollars.

“Half of that global revenue is going to be from medical, and we have proven leadership in medical,” he said. “We have doctors, PhDs, professors, which help us create technology with cannabinoids and cannabis.”

Bennett believes that Canopy Growth (NYSE: CGC) is well-positioned to dominate in the global cannabis market, but rates the stock a Hold based on its current valuation which he says captures its strong position in the market. His other Hold is Emerald Health Therapeutics (TSXV: EMH.VN), which is a small medical cannabis company that relies on partnerships for its supply.

Cronos Group (NASDAQ: CRON) has been generating a lot of headlines recently but Bennett thinks the stock is expensive, especially with its modest production capacity compared to a grower like Aurora, and rates it an Underperform. His other Underperform rating went to Hexo (TSX: HEXO.TO, OTC: HEXO) which Bennett says is floating on overoptimistic forecasts for its cash flow and is still in the honeymoon phase after its deal to collaborate with Molson Coors (NYSE: TAP).

While Bennett’s 250-page report only looked at companies that sell marijuana in countries where the drug is legal nationwide, like Canada, he did note that any pot company that wants to reach large-cap status will have to have a strong position in the U.S., which is projected to be the world’s largest cannabis market. 

Hemp—a source of the non-psychoactive ingredient cannabidiol, or CBD—was recently legalized in the U.S. and could see sales above $32 billion by 2022. Bennett says that all of the companies he now covers “should still be establishing optionality for when/if U.S. regulations change.”

And the winds of change are blowing in the U.S. On Thursday, Senator Cory Booker, D-N.J., introduced a bill to legalize the drug nationwide. The bill comes as states are increasingly legalizing marijuana in some capacity and public opinion continues to shift in favor of legalization.

Bennett says that investors shouldn’t be concerned that “weed is just another agricultural commodity” that will see price drops from oversupply. Premium pot won’t be commoditized, according to Bennett, and he doesn’t believe we’ll see a cannabis supply glut until mid-2021 at the earliest.

“If you can deliver a top quality experience,” Bennett wrote. “You will be able to charge a premium.”

By the way, if you liked this article, you'll LOVE this Meaty free training I just published on the top 3 questions and challenges every investor faces AND how to overcome them. It's titled "10k into $2.4 Million in 18 months" and you can grab it for free here

There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Companys software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.

FREE TRADING WEBINAR - TRADERSPRO PRESENTS: Starting With Only $10,000 Retire With $2.4 Million? Click Here Now

Join Us Now